US Edition
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
- Professor Jonathan Barratt presented 100-week Phase 1/2 data on zigakibart for IgA nephropathy at the 62nd ERA Congress in Vienna.
- The study included 40 adult participants diagnosed through biopsy with IgAN who continued to exhibit proteinuria even after undergoing standard treatment, including the use of renin-angiotensin system inhibitors.
- Zigakibart, an anti-APRIL monoclonal antibody, showed a 60% proteinuria reduction, 74% drop in IgA, and stable kidney function with mostly mild side effects.
- Professor Barratt noted that APRIL inhibition may provide long-lasting renal protection and fundamentally modify IgAN's disease course beyond symptom control.
- These findings support zigakibart as a potential new cornerstone therapy for IgAN, with ongoing Phase 3 studies aimed at confirming long-term benefits and safety.
53 Articles
53 Articles
New data shows zigakibart sustains proteinuria remission and kidney function in IgA nephropathy
New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN).
Johnson City Press
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
VIENNA, June 4, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN). Findings presented today at the 62nd ERA…
Long-Term Study Confirms Sustained Efficacy and Safety of Zigakibart in IgA
In a significant advancement for the treatment of IgA nephropathy (IgAN), recent findings from a 100-week Phase 1/2 clinical trial have highlighted the promising long-term efficacy and safety profile of zigakibart, an investigational monoclonal antibody targeting the APRIL pathway. The data, unveiled at the 62nd European Renal Association (ERA) Congress in Vienna, Austria, underscore the potential of this innovative biologic therapy to alter the…
Coverage Details
Bias Distribution
- 59% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
